News Column

Study Findings from Fudan University Broaden Understanding of Gliomas (In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles)

August 13, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "To improve the solubility, bioavailability and anti-tumor effect of lapatinib, lapatinib-incorporated lipid nanoparticles (LTNPs) were prepared and characterized. The particle size of LTNPs was 88.6 nm with a zeta potential of 20 mV."

Our news journalists obtained a quote from the research from Fudan University, "Laptinib was loaded into LTNPs with a non-crystal structure as determined by FT-IR. In vitro, LTNPs could be effectively uptaken into C6 glioma cells at a concentration-dependent manner. In vivo, LTNPs showed a relative higher AUC, which was 5.27-and 3.21-fold as that of Tykerb and lapatinib suspension (LTS) group. LTNPs also showed highest glioma concentration, which may benefit from the enhanced permeability and retention effect and active targeting ability. In toxicity studies, LTNPs displayed a half lethal dose over 250 mg/kg. Repeated administering 30 mg/kg of LTNPs could led to toxicity to hematology which might owe to the bovine serum albumin, a foreign protein to mice. However, there was no organic change observed through HE staining."

According to the news editors, the research concluded: "LTNPs could target to glioma with high concentration and low side effect."

For more information on this research see: In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles. Current Pharmaceutical Biotechnology, 2014;14(12):1062-71. (Bentham Science Publishers - www.benthamscience.com; Current Pharmaceutical Biotechnology - www.benthamscience.com/cpb/index.htm)

The news correspondents report that additional information may be obtained from H. Gao, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, 826 Zhangheng Road, Shanghai, 201203, People's Republic of China. Additional authors for this research include C. Chen, Z. Xi, J. Chen, Q. Zhang, S. Cao and X. Jiang (see also Oncology).

Keywords for this news article include: Asia, Glioma, Shanghai, Oncology, Nanoparticle, Nanotechnology, Emerging Technologies, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters